Pritelivir reduces viral shedding and lesions better than valacyclovir, study shows
Dec. 20, 2016
| By Mary Engel / Fred Hutch News Service
The results of the phase 2, randomized, double-blind trial published today in JAMA showed that when people with genital herpes took a daily oral dose of pritelivir, they reduced their rate of viral shedding by half compared to when they took valacyclovir. They also had fewer genital sores and less pain.
New Hutch study predicts threshold of viral load for passing herpes from one person to another
March 25, 2014
| By Mary Engel
Fred Hutch researchers used mathematical models to predict viral loads below which transmission of the herpes virus is unlikely to occur. Preventing transmission is critical because there is no cure for herpes.
Largest study of herpes simplex virus type 2 to date finds asymptomatic carriers can transmit virus to partners
April 25, 2011
Persons who have tested positive for herpes simplex virus type 2 but do not have symptoms or genital lesions still experience virus shedding during subclinical episodes, suggesting a high risk of transmission from persons with unrecognized HSV-2 infection, according to a study in the April 13 issue of the Journal of the American Medical Association.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.